Aarti Pharmalabs Share Price
Sector: Biotechnology & Drugs
859.25 -13.00 (-1.49%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
857.20
Today’s High
888.65
52 Week Low
521.00
52 Week High
948.80
859.55 -13.30 (-1.52%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
857.00
Today’s High
881.00
52 Week Low
551.05
52 Week High
949.50
Key Metrics
- Market Cap (In Cr) 7777.53
- Beta -
- Div. Yield (%) 0.58
- P/B 3.92
- TTM P/E 24.93
- Sector P/E 22.43
- D/E 0
- Open Price 888.65
- Prev Close 872.25
Aarti Pharmalabs Analysis
Price Analysis
-
1 Week0.74%
-
3 Months14.72%
-
6 Month26.88%
-
YTD25.25%
-
1 Year40.6%
Risk Meter
- 49% Low risk
- 49% Moderate risk
- 49% Balanced Risk
- 49% High risk
- 49% Extreme risk
Aarti Pharmalabs News
Stock market today: Nifty 50 to global markets — seven stocks to buy or sell
3 min read . 04 Apr 2025Breakout stocks to buy or sell: Sumeet Bagadia recommends seven shares to buy
1 min read . 19 Mar 2025These five stocks rise up to 35% in one month despite weak Indian markets
2 min read . 26 Feb 2025Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
1 min read . 19 Feb 2025Aarti Pharmalabs Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 2115.07
- Selling/ General/ Admin Expenses Total
- 161.96
- Depreciation/ Amortization
- 86.9
- Other Operating Expenses Total
- 360.87
- Total Operating Expense
- 1737.61
- Operating Income
- 377.47
- Net Income Before Taxes
- 360.69
- Net Income
- 272.4
- Diluted Normalized EPS
- 30.06
- Period
- 2025
- Total Assets
- 2906.41
- Total Liabilities
- 916.5
- Total Equity
- 1989.91
- Tangible Book Valueper Share Common Eq
- 208.49
- Period
- 2025
- Cashfrom Operating Activities
- 331.56
- Cashfrom Investing Activities
- -413.9
- Cashfrom Financing Activities
- 65.43
- Net Changein Cash
- -16.9
- Period
- 2024
- Total Revenue
- 1852.61
- Selling/ General/ Admin Expenses Total
- 437.48
- Depreciation/ Amortization
- 73.24
- Other Operating Expenses Total
- 0
- Total Operating Expense
- 1539.8
- Operating Income
- 312.81
- Net Income Before Taxes
- 300.49
- Net Income
- 216.9
- Diluted Normalized EPS
- 23.93
- Period
- 2024
- Total Assets
- 2582.11
- Total Liabilities
- 825.07
- Total Equity
- 1757.04
- Tangible Book Valueper Share Common Eq
- 185.38
- Period
- 2024
- Cashfrom Operating Activities
- 216.35
- Cashfrom Investing Activities
- -214.56
- Cashfrom Financing Activities
- 9.72
- Net Changein Cash
- 11.51
- Period
- 2023
- Total Revenue
- 1945.23
- Selling/ General/ Admin Expenses Total
- 415.43
- Depreciation/ Amortization
- 62.54
- Other Operating Expenses Total
- 3.65
- Total Operating Expense
- 1665.33
- Operating Income
- 279.9
- Net Income Before Taxes
- 260.77
- Net Income
- 193.49
- Diluted Normalized EPS
- 21.39
- Period
- 2023
- Total Assets
- 2230.93
- Total Liabilities
- 672.44
- Total Equity
- 1558.49
- Tangible Book Valueper Share Common Eq
- 167.38
- Period
- 2023
- Cashfrom Operating Activities
- 250.12
- Cashfrom Investing Activities
- -157.8
- Cashfrom Financing Activities
- -163.46
- Net Changein Cash
- -71.15
- Period
- 2022
- Total Revenue
- 1199.94
- Selling/ General/ Admin Expenses Total
- 105.57
- Depreciation/ Amortization
- 42.12
- Other Operating Expenses Total
- 0.74
- Total Operating Expense
- 879.35
- Operating Income
- 320.59
- Net Income Before Taxes
- 155.38
- Net Income
- 122.25
- Diluted Normalized EPS
- 27.01
- Period
- 2022
- Total Assets
- 2039.9
- Total Liabilities
- 653.42
- Total Equity
- 1386.48
- Tangible Book Valueper Share Common Eq
- 150.32
- Period
- 2022
- Cashfrom Operating Activities
- -43.7
- Cashfrom Investing Activities
- -138.74
- Cashfrom Financing Activities
- 260.38
- Net Changein Cash
- 77.94
- Period
- 2021
- Total Revenue
- 0
- Other Operating Expenses Total
- 0
- Total Operating Expense
- 0
- Operating Income
- 0
- Net Income Before Taxes
- 0
- Net Income
- 0
- Diluted Normalized EPS
- 0
- Period
- 2021
- Total Assets
- 0.25
- Total Liabilities
- 0.02
- Total Equity
- 0.23
- Tangible Book Valueper Share Common Eq
- 0.03
- Period
- 2021
- Cashfrom Operating Activities
- 0
- Net Changein Cash
- 0
- Period
- 2025-03-31
- Total Revenue
- 563.78
- Selling/ General/ Admin Expenses Total
- 43.37
- Depreciation/ Amortization
- 22.82
- Other Operating Expenses Total
- 96.03
- Total Operating Expense
- 440.97
- Operating Income
- 122.81
- Net Income Before Taxes
- 114.62
- Net Income
- 88.34
- Diluted Normalized EPS
- 9.75
- Period
- 2025-03-31
- Total Assets
- 2906.41
- Total Liabilities
- 916.5
- Total Equity
- 1989.91
- Tangible Book Valueper Share Common Eq
- 208.49
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 331.56
- Cashfrom Investing Activities
- -413.9
- Cashfrom Financing Activities
- 65.43
- Net Changein Cash
- -16.9
- Period
- 2024-12-31
- Total Revenue
- 537.78
- Selling/ General/ Admin Expenses Total
- 41.63
- Depreciation/ Amortization
- 23.04
- Other Operating Expenses Total
- 92.23
- Total Operating Expense
- 432.21
- Operating Income
- 105.57
- Net Income Before Taxes
- 100.63
- Net Income
- 73.99
- Diluted Normalized EPS
- 8.16
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 458.03
- Selling/ General/ Admin Expenses Total
- 37.73
- Depreciation/ Amortization
- 20.88
- Other Operating Expenses Total
- 91.05
- Total Operating Expense
- 385.24
- Operating Income
- 72.79
- Net Income Before Taxes
- 71.77
- Net Income
- 54.62
- Diluted Normalized EPS
- 6.02
- Period
- 2024-09-30
- Total Assets
- 2776.51
- Total Liabilities
- 919.79
- Total Equity
- 1856.73
- Tangible Book Valueper Share Common Eq
- 194.75
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 111.64
- Cashfrom Investing Activities
- -175.04
- Cashfrom Financing Activities
- 80.58
- Net Changein Cash
- 17.17
- Period
- 2024-06-30
- Total Revenue
- 555.49
- Selling/ General/ Admin Expenses Total
- 39.23
- Depreciation/ Amortization
- 20.17
- Other Operating Expenses Total
- 81.56
- Total Operating Expense
- 479.2
- Operating Income
- 76.29
- Net Income Before Taxes
- 73.68
- Net Income
- 55.45
- Diluted Normalized EPS
- 6.12
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 505.77
- Selling/ General/ Admin Expenses Total
- 135.14
- Depreciation/ Amortization
- 19.13
- Other Operating Expenses Total
- 0
- Total Operating Expense
- 407.38
- Operating Income
- 98.39
- Net Income Before Taxes
- 95.75
- Net Income
- 65.25
- Diluted Normalized EPS
- 7.2
- Period
- 2024-03-31
- Total Assets
- 2582.11
- Total Liabilities
- 825.07
- Total Equity
- 1757.04
- Tangible Book Valueper Share Common Eq
- 185.38
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 216.35
- Cashfrom Investing Activities
- -214.56
- Cashfrom Financing Activities
- 9.72
- Net Changein Cash
- 11.51
- Period
- 2023-12-31
- Total Revenue
- 448.69
- Selling/ General/ Admin Expenses Total
- 36.16
- Depreciation/ Amortization
- 18.77
- Other Operating Expenses Total
- 72.42
- Total Operating Expense
- 371.78
- Operating Income
- 76.91
- Net Income Before Taxes
- 73.82
- Net Income
- 52.76
- Diluted Normalized EPS
- 5.82
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Aarti Pharmalabs Technical
Moving Average
SMA
- 5 Day863.79
- 10 Day865.79
- 20 Day889.88
- 50 Day825.44
- 100 Day773.86
- 300 Day704.22
Aarti Pharmalabs Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Shilpa Medicare
- 861.2
- -8.3
- -0.95
- 1003.2
- 530.5
- 8421.75
- Strides Pharma Science
- 896.4
- 10.3
- 1.16
- 906.9
- 412.71
- 8210.97
- Aarti Pharmalabs
- 859.25
- -13
- -1.49
- 948.8
- 521
- 7777.53
- Fdc
- 480.85
- 6.4
- 1.35
- 659
- 358.95
- 7835.32
- Supriya Lifescience
- 691
- 11.3
- 1.66
- 841.7
- 368.6
- 5574.08
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Shilpa Medicare
- 86.77
- 3.54
- 3.27
- 5.17
- Strides Pharma Science
- 23.26
- 3.2
- -1.22
- -1.07
- Aarti Pharmalabs
- 29.04
- 3.98
- -
- -
- Fdc
- 28.96
- 3.39
- 13.26
- 14.75
- Supriya Lifescience
- 29.15
- 5.5
- 22.63
- 25.45
Aarti Pharmalabs Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 10-May-25
- Audited Results & Final Dividend
- 05-Feb-25
- Quarterly Results, Dividend & Others
- 28-Oct-24
- Quarterly Results
- 05-Aug-24
- Quarterly Results
- 13-May-24
- Audited Results & Final Dividend
- 07-Feb-24
- Quarterly Results & Interim Dividend
- 07-Nov-23
- Quarterly Results
- 05-Aug-23
- Quarterly Results
- 12-May-23
- Audited Results
- Meeting Date
- Announced on
- Purpose
- 07-Aug-24
- 16-Jul-24
- AGM
- 14-Sept-23
- 05-Aug-23
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 12-May-25
- -
- -
- 2.5
- 05-Feb-25
- 14-Feb-25
- 14-Feb-25
- 2.5
- 13-May-24
- 31-Jul-24
- 31-Jul-24
- 1
- 07-Feb-24
- 19-Feb-24
- 16-Feb-24
- 2


